دورية أكاديمية
Cytoreductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval-ISPSM Collaborative Study.
| العنوان: | Cytoreductive Surgery with HIPEC as Primary Treatment for Advanced Epithelial Ovarian Carcinoma: Upfront or Interval-ISPSM Collaborative Study. |
|---|---|
| المؤلفون: | Somashekhar SP; Department of Surgical & Gynecological Oncology, Aster International Institute of Oncology, Aster Hospital, Bangalore, India., Ramya Y; Apollo BGS Hospital, Mysore, India., Ashwin KR; Department of Surgical & Gynecological Oncology, Aster International Institute of Oncology, Aster Hospital, Bangalore, India., Fernandes AM; Department of Surgical & Gynecological Oncology, Aster International Institute of Oncology, Aster Hospital, Bangalore, India., Ahuja V; Department of Surgical & Gynecological Oncology, Aster International Institute of Oncology, Aster Hospital, Bangalore, India., Namachivayam AK; Department of Data Science, Alke Research Private Limited, Bengaluru, India., Kumar CR; Department of Surgical & Gynecological Oncology, Aster International Institute of Oncology, Aster Hospital, Bangalore, India. |
| المصدر: | Indian journal of surgical oncology [Indian J Surg Oncol] 2023 Jun; Vol. 14 (Suppl 1), pp. 226-232. Date of Electronic Publication: 2023 May 09. |
| نوع المنشور: | Journal Article |
| اللغة: | English |
| بيانات الدورية: | Publisher: Springer India Country of Publication: India NLM ID: 101532448 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0975-7651 (Print) Linking ISSN: 09757651 NLM ISO Abbreviation: Indian J Surg Oncol Subsets: PubMed not MEDLINE |
| أسماء مطبوعة: | Original Publication: New Delhi : Springer India |
| مستخلص: | Cytoreductive surgery with HIPEC has shown promising results in the interval setting of advanced epithelial ovarian cancer. Its role in upfront setting has not yet been established. All eligible patients underwent CRS-HIPEC as per institution protocol. Relevant data was collected prospectively in institutional HIPEC registry and analyzed retrospectively for the study period from February 2014 to February 2020. Out of 190 patients, 80 underwent CRS-HIPEC in upfront setting and 110 in interval setting. The median age was 54 ± 7.45 years, upfront group had higher PCI (14.1 ± 8.75 vs. 9.6 ± 5.2. 2), and required longer duration of surgery (10.6 ± 1.73 vs. 8.4 ± 1.71 h) had more blood loss (1025 ± 668.76 vs. 680 ± 302.23 ml). The upfront group required more diaphragmatic resections, bowel resections, and multivisceral resections. The overall G3-G4 morbidity was comparable (25.4% vs. 27.3%), upfront group had more surgical morbidity (20% vs. 9.1%) whereas interval group had more medical morbidity, i.e., electrolyte imbalance and hematological. After a median follow-up of 43 months, median DFS was 33 months in the upfront vs. 30 months in the interval group, p = 0.75, median OS was 46 months interval group and was not yet achieved in upfront group.( p = 0.13). Four-year OS was 85% vs. 60%. In patients of advanced EOC upfront CRS HIPEC showed promising outcomes and trend towards better survival with similar morbidity and mortality. The upfront group had more surgical morbidity whereas interval group had more medical morbidity. Multiinstitutional randomized studies are needed to define patient selection and study morbidity patterns and compare the outcomes between CRS-HIPEC in the upfront and interval setting for advanced epithelial ovarian cancer. Competing Interests: Competing InterestsThe authors declare no competing interests. (© The Author(s), under exclusive licence to Indian Association of Surgical Oncology 2023. Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.) |
| References: | Lancet. 2015 Jul 18;386(9990):249-57. (PMID: 26002111) N Engl J Med. 1995 Mar 9;332(10):629-34. (PMID: 7845426) N Engl J Med. 2010 Sep 2;363(10):943-53. (PMID: 20818904) J Clin Oncol. 2007 Aug 20;25(24):3621-7. (PMID: 17704411) Eur J Cancer. 2016 May;59:22-33. (PMID: 26998845) Int J Gynecol Cancer. 2016 Sep;26(7):1354-63. (PMID: 27648648) J Clin Oncol. 2008 Jan 1;26(1):83-9. (PMID: 18025437) Clin Exp Metastasis. 2021 Apr;38(2):255. (PMID: 31811526) Int J Gynecol Cancer. 2012 Mar;22(3):380-5. (PMID: 22266934) Am J Surg. 2011 Oct;202(4):481-6. (PMID: 21474115) Gynecol Oncol. 2007 Apr;105(1):211-7. (PMID: 17239941) J Clin Oncol. 2016 Oct 1;34(28):3460-73. (PMID: 27502591) J Clin Oncol. 2002 Mar 1;20(5):1248-59. (PMID: 11870167) Eur J Cancer. 2016 Sep;64:22-31. (PMID: 27323348) N Engl J Med. 2018 Jan 18;378(3):230-240. (PMID: 29342393) Cochrane Database Syst Rev. 2016 Jan 09;(1):CD006014. (PMID: 26747297) Gynecol Oncol. 2013 Nov;131(2):437-44. (PMID: 23994107) Gynecol Oncol. 1998 Dec;71(3):431-6. (PMID: 9887245) PLoS One. 2017 Oct 23;12(10):e0186725. (PMID: 29059209) Eur J Surg Oncol. 2011 Jan;37(1):4-9. (PMID: 21112721) Natl Cancer Inst Monogr. 1975 Oct;42:101-4. (PMID: 1234624) Cancer. 2009 Mar 15;115(6):1234-44. (PMID: 19189349) G Chir. 1999 Mar;20(3):81-6. (PMID: 10217864) Ann Surg. 2009 Aug;250(2):187-96. (PMID: 19638912) |
| فهرسة مساهمة: | Keywords: Advanced epithelial ovarian cancer; Interval CRS HPEC; Morbidity; Upfront CRS HIPEC; Upfront versus interval CRS HIPEC |
| تواريخ الأحداث: | Date Created: 20230626 Latest Revision: 20240603 |
| رمز التحديث: | 20240603 |
| مُعرف محوري في PubMed: | PMC10284758 |
| DOI: | 10.1007/s13193-023-01747-3 |
| PMID: | 37359935 |
| قاعدة البيانات: | MEDLINE |
Find this article in full text from Springer Verlag. 
Full Text Finder | تدمد: | 0975-7651 |
|---|---|
| DOI: | 10.1007/s13193-023-01747-3 |